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AbstrAct
Objectives Assess the impact of selective prohibition and 
seizure of novel psychoactive substances (NPS) supply 
on NPS use prevalence within psychiatric admissions 
and evaluate demographic characteristics of current NPS 
users.
Design A 6-month retrospective cross-sectional analysis 
of discharge letters between 1 October 2015 and 31 
March 2016.
setting General psychiatry inpatients and intensive home 
treatment team (IHTT) community patients at a psychiatric 
hospital in a Scottish city.
Participants All participants were between the ages of 
18 and 65 years. After application of exclusion criteria, 
473 discharge letters of general psychiatry patients 
were deemed suitable for analysis and 264 IHTT patient 
discharge letters were analysed.
Interventions A nationwide temporary class drug 
order (TCDO) was placed on 10 April 2015 reclassifying 
methylphenidate-related compounds as class B 
substances. On 15 October 2015, local forfeiture orders 
were granted to trading standards permitting the seizure of 
NPS supplies.
Primary and secondary outcome measures The 
primary outcome measure was to determine the 
prevalence of NPS use in two cohorts. Second, 
demographic features of patients and details regarding 
their psychiatric presentation were analysed.
results The prevalence of NPS use in general psychiatry 
and IHTT patients was 6.6% and 3.4%, respectively. 
Inpatients using NPS compared with non-users were more 
likely to be men (OR 2.92, 95% CI 1.28 to 6.66, P=0.009), 
have a forensic history (OR 5.03, CI 2.39 to 10.59, 
P<0.001) and be detained under an Emergency Detention 
Certificate (OR 3.50, CI 1.56 to 7.82, P=0.004). NPS users 
were also more likely to be diagnosed under International 
Statistical Classification of Diseases and Related Health 
Problems, Version 10, F10–19 (OR 9.97, CI 4.62 to 21.49, 
P<0.001).
conclusions Compared with previous work, psychiatric 
inpatient NPS use has fallen. NPS continue to be used 
by a demographic previously described resulting in 
presentations consistent with a drug-induced psychosis 
and at times requiring detention under the Mental 
Health Act. Further research is required to evaluate the 
effectiveness of the recent prohibition of all NPS.
IntrODuctIOn
background
In recent years, a new public health issue has 
arisen: novel psychoactive substances (NPS), 
more commonly known as ‘legal highs’. The 
European Monitoring Centre for Drugs and 
Drug Addiction (EMCDDA) defines an NPS 
as a drug not controlled by UN drug conven-
tions with potential to cause as much public 
health risk as classic illicit drugs.1 Attempts 
have been made to classify NPS chemically,2 
of which synthetic cannabinoids (cannabis 
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Research
strengths and limitations of this study
 ► Recent public health interventions concerning novel 
psychoactive substances (NPS) have been evaluated, 
specifically their association with a reduction in the 
prevalence of NPS use in a psychiatric population.
 ► The strain placed on services by NPS use has been 
quantified by studying the duration of patients’ 
admissions and the likelihood that they are detained 
under the Mental Health Act.
 ► As the NPS user sample was relatively small 
compared with previous work, figures pertaining to 
the demographic features of this group should be 
interpreted with caution.
 ► A number of the study outcomes were poorly 
recorded for in discharge letters, which may be 
accounted for by the variation in the quality of 
discharge letters.
 ► The study period encompasses a 6-month period 
following the issue of forfeiture orders on 15 October 
2015; therefore, it is not possible to comment if 
the reduction of NPS use within this population 
is more attributable to a particular one of the two 
interventions.
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Figure 1 Flow chart of inclusion/exclusion criteria and patient groups. Subgroups of the lowest tier in the flow chart were 
analysed collectively as non-NPS users. CAMHS, Child and Adolescent Mental Health Services; ECT, electroconvulsive therapy; 
NPS, novel psychoactive substance; REH, Royal Edinburgh Hospital.
replacements) and synthetic cathinones (stimulants) 
account for the majority.3 However, in 2014 alone over 
a hundred new NPS were introduced to the market, 
signifying the challenges in studying and classifying such 
substances.3 
Over the past decade, NPS have been assimilated into 
the repertoire of drugs available to habitual drug users.4 
Sophisticated marketing of NPS has rendered them as 
socially acceptable and safe,5 despite their involvement in 
numerous drug-related deaths.6 Until recently, NPS have 
escaped prohibitive legislation by including labels on 
packaging: ‘not for human consumption’ or ‘for research 
only’,7 despite the contrary insinuations made elsewhere.
In Edinburgh, during 2014,5 ethylphenidate, a meth-
ylphenidate derivative, resulted in a significant burden 
for Police Scotland; the incidence of legal-high related 
casualties increased amidst reports of ‘bizarre and violent 
behaviour’.8 As well as admissions to acute mental health 
services, a cluster of serious soft-tissue infections and 
necrotic ulcers resulted from parenteral ethylphenidate 
use.8 9 Ethylphenidate was first recognised in UK ‘head-
shops’ (drug paraphernalia shops) in November 2011 
via the UK Forensics Early Warning System10 and was 
subsequently reported to the EMCDDA.7 However, its use 
had already been widely discussed on online user forums 
before this time.11 Its effects bear similarity to that of 
cocaine and, to some extent, amphetamines, including 
euphoria, increased sociability,12 tachycardia, hyperten-
sion, palpitations,13 multisensory hallucinations9 and a 
considerable urge to reuse.12 14 NPS in general have been 
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Figure 2 The percentage of novel psychoactive 
substance (NPS) users and non-NPS users admitted in 
fortnightly intervals between October 2015 and March 2016. 
associated with various psychiatric symptoms, which often 
present as an acute transient psychotic episode15 although 
the long-term impact on mental health is unknown. Ethyl-
phenidate has been implicated in numerous fatalities6 16 
and was, in one study, discovered in the possession of two 
subjects following suicide, suggesting a possible associa-
tion with psychiatric illness.17
On 10 April 2015, the UK government responded by 
placing a temporary class drug order (TCDO) under 
the Misuse of Drugs Act 1971 on methylphenidate deriv-
atives making supply and production, but not posses-
sion, punishable by imprisonment.18 19 Police Scotland 
reported a reduction in parenteral infections, publicly 
discarded needles and emergency admissions since this 
time.20 Forfeiture orders were granted on 15 October 
2015 from the Sheriff Court in Edinburgh to Trading Stan-
dards permitting seizure of all NPS from head-shops.21 
More recently, the Psychoactive Substances Act (2016) 
was imposed, which criminalises any NPS—a so-called 
blanket ban.22 However, other substances classified under 
the Misuse of Drugs Act such as mephedrone have, since 
their selective banning, become integrated into the club-
bing environment23 and distributed under the guise of 
legal NPS,24 raising questions as to how effective specific 
legislative bans are.
In recent years, the public health issue of NPS use has 
been widely researched, including a previous study at this 
centre. Work by Stanley et al established that 22.2% of 
inpatients admitted to acute psychiatric wards at the Royal 
Edinburgh Hospital were using NPS, 59.3% of whom had 
psychiatric symptoms attributable to their drug use.25 
Since legislative changes have been implemented, no 
research has been conducted to analyse ongoing trends 
in NPS use.
Objectives
This study aimed to examine the possible impact of the 
recent public health interventions on NPS-related psychi-
atric admissions, building on the findings of a previous 
study by Stanley et al.25 In addition to examining admis-
sions to the acute psychiatric inpatient wards at the Royal 
Edinburgh Hospital, patients admitted to the inten-
sive home treatment team (IHTT), a community-based 
psychiatric crisis team, covering the same catchment area 
as the Royal Edinburgh Hospital, were also included. The 
study aimed to evaluate how effective recent public health 
interventions have been in reducing NPS use, as reflected 
in NPS-related admissions to these two services. The 
primary hypothesis was that the interventions made on 
a national and local level would have reduced the prev-
alence of NPS use in patients admitted to these services.
MethODs
study design and setting
This study was a retrospective cross-sectional review of 
discharge letters written for two cohorts of psychiatric 
patients—general psychiatry inpatients and communi-
ty-based IHTT patients—at the Royal Edinburgh Hospital in 
Edinburgh, UK. Discharge letters were written by medical 
staff for inpatients; IHTT discharge letters were written by 
community psychiatric nurses and reviewed by medical staff.
Participants
Adult patients (18–65 years old) admitted to the Royal 
Edinburgh Hospital between 1 October 2015 and 31 
March 2016 were identified from the TrakCare Elec-
tronic Patient Record (InterSystems) database.26 Only 
patients admitted to general psychiatry who had been 
subsequently discharged from hospital by 30 June 2016 
were included in the study. Those admitted to specialist 
services or admitted as inpatient day-cases for electrocon-
vulsive therapy were excluded (figure 1). All adult patients 
admitted to IHTT over the same period were included.
Data collection
SAP BusinessObjects (SAP)27 was used by KHB and RMW 
to extract details regarding patient admissions, including 
Principal Diagnosis and Code (consistent with Interna-
tional Statistical Classification of Diseases and Related 
Health Problems, Version 10 (ICD-10)),28 duration of 
admission and legal status (Mental Health (Care and 
Treatment) (Scotland) Act 200329while in hospital, which 
was categorised as informal, Emergency Detention Certif-
icate (EDC), Short-Term Detention Certificate (STDC) 
or Compulsory  Treatment Order (CTO). Patients were 
assigned subject numbers to ensure anonymity.
Additional study outcomes relating to patient demo-
graphics (age, gender, employment status and home 
circumstances), forensic history (any forensic history of 
note and custodial sentences), substance use (NPS use, 
contribution to psychiatric presentation, name of NPS, 
route of administration and other substance use) and 
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any psychiatric symptoms recorded during admission 
were collected from patient discharge letters on e-Health 
systems by KHB. Such data were collected during clerking 
of patients and routine consultations; thus, reporting 
of these outcomes were dependent on clinical inquiry 
and patient self-reporting. Some discharge letters were 
extractable as free-text from TrakCare (Intersystems) 
using SAP BusinessObjects. Others were only available as 
PDF (Portable Document Format) files uploaded to the 
linked document storage system SCI-Store.30 Both loca-
tions were searched. All data were recorded in the data 
collection tool provided in the online supplementary file.
When recorded, NPS brand names were cross-checked 
on an online database of NPS to reveal the active ingredi-
ents reported to be present.31 These chemicals were then 
classified in accordance with the Drugs Wheel to provide 
an NPS type32; supporting evidence was found elsewhere 
if these chemicals were not reported in the Drug Wheel.33 
Where study outcomes were not recorded in discharge 
letters, these were assumed to be negative and grouped 
with explicitly negative data. Patients referred to IHTT 
were identified using SAP and the above study outcomes 
were collected from IHTT discharge letters either within 
a free-text TrakCare extract or uploaded PDFs as above. 
Data collection was repeated for a sample of subjects by 
HMH for quality control purposes.
statistical methods
Statistical analysis was carried out using SPSS V.22.0.0.1 
(IBM). Independent two-sample Student’s t-tests were 
used to assess the differences in continuous depen-
dent variables between NPS users and non-NPS users. 
ORs were generated and Pearson χ2 tests were used to 
compare differences between these groups for remaining 
categorical variables; Fisher’s exact test and Phi/Cram-
er’s V symmetric measures were performed where appro-
priate. Two-tailed two-sample Z-tests were performed for 
comparisons between the proportion of NPS users in this 
study and those in Stanley et al a study conducted under 
the same methodology that reported the prevalence of 
NPS use in the general psychiatry population between 
July and December 2014.25
ethics and database protection
This study was assessed by the local clinical governance 
team who deemed that it did not require ethics committee 
approval. Data were collected into an Excel spreadsheet 
using a coded ID number which could not be used to 
retrospectively identify individual patients. This spread-
sheet was password protected and stored on NHS servers 
only. The password was available only to the authors; each 
had access via their NHS user ID which allowed tracking 
of changes made.
results
A total of 473 general psychiatry inpatient cases were 
included in the analysis after application of the exclusion 
criteria (figure 1). Of these, 31 patients were reported 
to be currently using NPS on admission. A two-tailed 
two-sample Z-test between the proportion of NPS users 
in this population (6.6%, n=473) and of that in Stanley 
et al (22.2%, n=488)25 revealed a statistically significant 
difference (z=6.7, P<0.001). A total of 264 patients were 
discharged from IHTT, of which nine cases (3.4%) were 
identified as NPS users at the time of admission. Across 
both cohorts, the prevalence of NPS use was 5.4%.
For general psychiatry and IHTT NPS users, the types of 
NPS were recorded in 38.7% and 11.1% of cases, respec-
tively. NPS use was recorded to contribute to the psychi-
atric presentation 77.4% and 22.2% of the time. Of all 
NPS products identified in the general psychiatry cohort, 
including multiple NPS in individual patients, 24.2% 
contained stimulants (ethylphenidate, methiopropamine 
(MPA) and 3-fluorophenmetrazine (3-FPM)) and 18.2% 
were synthetic cannabinoids. Three of the recorded NPS 
products have been reported to include two active ingre-
dients; ‘Magic crystals’ are reported to include 3-FPM 
and ethylphenidate whereas ‘Pink panther’ is reported to 
include MDAI, an empathogen, and MPA and ‘K-Pax’ is 
reported to include methoxphenidine, a dissociative, in 
addition to 3-FPM.31 34 The use of MPA could be identi-
fied in only one case of the IHTT cohort (11.1%). Data 
from the IHTT cohort were excluded from further anal-
ysis due to insufficient recording of outcome measures in 
discharge letters.
Figure 2 shows the percentage of admissions for NPS 
users and non-NPS users over the study period (October–
March). The month of October accounted for the largest 
proportion of NPS user admissions in which 16.1% were 
admitted in the first fortnight and 19.4% in the remainder 
of the month (a total 35.5% across October). However, 
compared with non-NPS users these figures were not 
statistically significant.
The collective length of admission for all NPS users 
amounted to 4.41% of the total length of admission for 
all inpatients. Mean length of admission between NPS 
users and non-NPS users was not statistically significant.
NPS users were significantly more likely to be detained 
under the Mental Health Act (MHA) than non-NPS 
users (OR 3.37, 95% CI1.57 to 7.21, P=0.002). When indi-
vidual modes of detention were considered (EDC, STDC 
and CTO), there was a statistically significant difference 
between NPS users and non-NPS users only in detention 
under an EDC, where 32.3% of NPS users were detained 
under this order compared with 12.0% of non-NPS users 
(OR 3.50, CI 1.56 to 7.82, P=0.004).
The demographic features of NPS users compared with 
non-NPS users are shown in table 1. Significant differ-
ences were observed between NPS users and non-NPS 
users for mean age (35.1±9.8 (SD) years vs 40.0±11.7 
(SD) years, P=0.023). Furthermore, a bimodal distribu-
tion of age ranges emerged in NPS users where peaks 
were observed in the 18–25 and 41–45 age ranges. Age 
of NPS users was significantly more likely to be within 
the latter range compared with non-NPS users (OR 2.87, 
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Table 1 Demographic features of NPS users and non-NPS users
NPS users (n=31) Per cent Non-NPS users (n=442) Per cent
Mean age (SD) 35.1 (9.8)* 40 (11.7)*
Gender
  Male 23* 74.19 218* 49.3
  Female 8* 25.81 221* 50.0
  Transgender 0 0.00 3 0.7
Employment
  Unemployed 12 38.71 176 39.8
  Student 1 3.23 17 3.8
  Employed 1 3.23 51 11.5
   Full time 1 3.23 44 10.0
   Part time 0 0.00 7 1.6
  Self-employed 0 0.00 8 1.8
  Retired 0 0.00 1 0.2
  Prison 0 0.00 6 1.4
  Not recorded 17 54.84 183 41.4
Home circumstances
  Independent 12 38.71 250 56.6
   Fully independent 5 16.13 165 37.3
   Benefits 5 16.13 71 16.1
   Council tenancy 2 6.45 14 3.2
  Supported 6 19.35 14 3.2
  Homeless 2 6.45 21 4.8
  Prison 0 0.00 1 0.2
  Not recorded 11 35.48 138 31.2
Forensic history 17** 54.84 86** 19.5
Previous custodial sentence 4 12.90 27 6.1
Use of MHA
  Any use of MHA 20 64.52 155 35.1
  EDC 10 32.26 53 12.0
  STDC 12 38.71 133 30.1
  CTO 1 3.23 30 6.8
ICD-10 diagnosis groupings
  F00–09 0 0.00 3 0.7
  F10–19 17** 54.84 48** 10.86
  F20–29 11 35.48 122 27.60
  F30–39 1** 3.23 144** 32.58
  F40–49 1 3.23 42 9.50
  F50–59 0 0.00 2 0.45
  F60–69 1 3.23 53 11.99
  F70–79 0 0.00 1 0.23
  F80–89 0 0.00 1 0.23
  Not recorded 0 0.00 16 3.62
  Other 0 0.00 11 2.49
Substance use
  Cannabis 18** 58.10 93** 21.00
Continued
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NPS users (n=31) Per cent Non-NPS users (n=442) Per cent
Mean age (SD) 35.1 (9.8)* 40 (11.7)*
  Alcohol 8 25.80 120 27.10
  Non-substitute opiates 8* 25.80 43* 9.70
  Substitute opiates 7 22.60 46 10.40
  Other 7* 22.60 17* 3.80
  MDMA 4* 12.90 16* 3.60
  Amphetamines 3 9.70 25 5.70
  Cocaine 3 9.70 39 8.80
  Benzodiazepines 3 9.70 34 7.70
Any substance use 26** 83.90 217** 49.10
Denotes a statistically significant difference between NPS users and non-NPS users, *P<0.05 and **P<0.001.
CTO, compulsory treatment order; EDC, Emergency Detention Certificate; F00–F09, Organic, including symptomatic, mental disorders; 
F10–19, Mental and behavioural disorders due to psychoactive substance use; F20–F29, Schizophrenia, schizotypal and delusional disorders; 
F30–39 Mood (affective) disorders; F40–F49, Anxiety, dissociative, stress-related, somatoform and other non-psychotic mental disorders; 
F50–F59, Behavioural syndromes associated with physiological disturbances and physical factors; F60–F69, Disorders of adult personality 
and behaviour; F70–F79, Mental retardation; F80–89, Disorders of psychological development; ICD, International Statistical Classification of 
Diseases and Related Health Problems;  MDMA, 3,4-methylenedioxymethamphetamine; MHA, Mental Health Act; NPS, novel psychoactive 
substances; Other, b and emotional disorders with onset usually occurring in childhood and adolescence/unspecified mental disorder; 
STDC, Short-Term Detention Certificate.
Table 1 Continued 
Figure 3 The percentage of NPS users and non-NPS 
users assigned principal diagnoses in accordance with ICD-
10 groups. *Denotes a statistically significant difference 
between NPS users and non-NPS users (χ2), P<0.001. ICD, 
International Statistical Classification of Diseases and Related 
Health Problems, Version 10; NPS, novel psychoactive 
substances.
95% CI 1.29 to 6.37, P=0.007). NPS users were more 
likely to be men (OR 2.92, CI 1.28 to 6.66, P=0.009) 
and have a forensic history recorded in their discharge 
letter (OR 5.03, CI 2.39 to 10.59, P<0.001) compared 
with non-NPS users. However, no statistical differences 
between NPS users and non-NPS users were observed 
in the proportions of patients recorded to have served 
custodial sentences.
NPS users were significantly more likely to use illicit 
substances other than NPS compared with non-NPS users 
(OR 5.44, 95% CI 2.05 to 14.43, P<0.001). Compared 
with non-NPS users, NPS users were significantly more 
likely to use cannabis (OR 4.56, CI 2.17 to 9.58, P<0.001), 
non-substitute opiates (OR 2.85, CI 1.16 to 7.03, P=0.018), 
3,4-methylenedioxymethamphetamine (MDMA) (OR 
3.94, CI 1.23 to 12.61, P=0.013) and other uncategorised 
substances, which included hallucinogens and illegally 
acquired prescription drugs (OR 5.88, CI 1.97 to 17.58, 
P<0.001).
Figure 3 reveals that ICD-10 diagnosis groupings for 
NPS users compared with non-NPS users were more likely 
to be F10–19 (OR 9.97, 95% CI 4.62 to 21.49, P<0.001) 
and less likely to be F30–39 (OR 0.07, CI 0.009 to 0.516, 
P<0.001). The most significant difference in diagnosis 
was for mental and behavioural disorders due to multiple 
drug use and use of other psychoactive substances disorder 
(ICD-10 F19), (OR 28.66, CI 11.85 to 69.30, P<0.001).
NPS users compared with non-NPS users were found to 
be significantly more likely to present with paranoia (OR 
2.34, 95% CI 1.08 to 5.08, P=0.036) and thought disorder 
(3.44, CI 1.50 to 7.90, P=0.002) and less likely to present 
with low mood (OR 0.29, CI 0.11 to 0.76, P=0.007) and 
suicidal thoughts (OR 0.129, CI 0.03 to 0.550, P=0.001).
DIscussIOn
Principal findings
The present study builds on the findings made by Stanley et 
al25 by evaluating the impact of recent public health changes. 
As well as acute psychiatric inpatients, a second cohort was 
included, which comprised patients admitted to IHTT—a 
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population previously not considered. We hypothesised that 
since public health interventions, the prevalence of NPS 
use in psychiatric patients has fallen. In contrast to the prev-
alence of 22.2% found by the previous work in psychiatric 
inpatients,25 the present data revealed a prevalence of NPS 
use in this group of 6.6% following recent public health 
interventions—a 15.6% reduction. Additionally, the prev-
alence of NPS use reported in discharge letters from the 
IHTT cohort was found to be 3.4%. The present study found 
that of the NPS types recorded, a considerable proportion 
(24.2%) were stimulants, several of which are reported to 
include more than one active ingredient. The relative popu-
larity of this diverse group of chemicals may suggest that 
other compounds have been recently adopted by NPS users 
as a substitute for ethylphenidate since the TCDO.
strengths and weaknesses
Unfortunately, a large proportion of demographic outcome 
measures (54.84% employment and 35.48% home circum-
stances) were not recorded in discharge letters and due to 
the relatively small sample size, it is not possible to comment 
on these. Generally, demographic characteristics were similar 
to those found in the previous study25: NPS users were more 
likely to be men, polysubstance misuse was more likely and 
mean age was similar (35.1 compared with 36.1 years old). 
The age distribution of NPS users was studied more thor-
oughly, however, and a bimodal distribution was observed 
with peaks in the 18–25 and 41–45 age groups, the latter of 
which was significant compared with non-NPS users. This 
is broadly in agreement with the findings of the DrugWise 
NPS: Come of Age report,35 which suggested that NPS use is 
not confined to a single generation; NPS perhaps appeal to 
the 18–25 age group as have ‘club drugs’ like mephedrone4 
and ‘party pills’, such as those containing piperazine 
compounds.36 Conversely, the 41–45 age group may use 
NPS as drug substitutes—so-called substance displacement, 
a phenomenon that has previously reported for synthetic 
cannabinoids.37 As in the previous work,25 the present study 
suggested that NPS users were more likely to use cannabis 
concomitantly; however, rather than a higher prevalence 
of substitute opiates it was found that NPS users within this 
study were more likely to use non-substitute opiates and 
MDMA. It is possible that these drug choices relate again 
to the prominent age groups observed—MDMA users aged 
18–25 years have previously been shown to be more likely 
to use NPS, particularly synthetic cannabinoids, phenethyl-
amines and synthetic cathinones38; and ethylphenidate has 
been implicated in opiates users, which may correspond to 
the 41–45 age group.16 17 To assess differences in diagnoses 
between NPS users and non-NPS users, this study adopted 
a standardised approach by recording ICD-10 codes. The 
most common principal diagnosis assigned to NPS users was 
F19.5 (mental and behavioural disorders due to multiple 
drug use and use of other psychoactive substances: psychotic 
disorder). Previous work also found that this was the most 
commonly recorded diagnosis.25 On the basis of the present 
data, it is not possible to demonstrate a causal link between 
NPS and drug-induced psychosis. However, evidence from 
this study suggests that public health interventions may be 
effective in reducing the prevalence of NPS use in individ-
uals vulnerable to their effects on mental state. In an effort 
to quantify the strain of these admissions on psychiatric 
services, length of stay and use of the MHA29 were examined. 
Compared with Stanley et al,25 it was found that almost double 
the proportion of NPS users in this study were detained and 
significant differences were observed in the use of EDC 
between NPS users and non-NPS users. Initially this could, 
in combination with the above findings regarding diag-
nosis, suggest that more users than in the earlier study are 
presenting severely psychotic enough to warrant detention. 
However, this finding should be interpreted with caution 
as changes in the working patterns of medical staff locally 
has consequently resulted in more out-of-hours detentions 
placed by junior medical staff, who are only able to detain 
under an EDC. This change in practice may be acting as a 
confounding factor for an apparent increase in this type of 
detention for patients. Psychotic episodes in patients using 
synthetic cannabinoids have been documented previously as 
transient and acute39; no significant differences in average 
length of stay between NPS users and non-NPS users were 
found. The total length of stay in this group accounts for 4% 
of length of stay across all patients, which is a smaller propor-
tion than the proportion of NPS users within the general 
psychiatry cohort (6.6%). Thus, no disproportionate or 
considerable strain on services has been observed at present 
and due to lack of data from Stanley et al,25 it is not possible 
to evaluate if there has been any significant change.
limitations and future research
The study period covered 1 October 2015 to 31 March 
2016, a 6-month period encompassing significant public 
health changes with regard to NPS. It is unfortunately not 
possible to say which of the two public health changes is 
associated with the reduction in prevalence of NPS use. 
However, these interventions together represent a ban 
and a seizure of supplies, and conclusions can be drawn 
about the collective impact of these changes. While 
comparisons may be made with the previous study, it is 
important to bear in mind that Stanley et al25 examined 
admissions during the months of July and August and it 
is possible that seasonal differences may have some influ-
ence here.40 One limitation is that the sample size of 
patients admitted to hospital/IHTT following NPS use is 
small and it most likely represents a small minority of the 
whole NPS using population. Recent data have estimated 
that 937 000 people aged 16–59 in England and Wales had 
used an NPS at least once and 279 000 in the past year.41 
With limited data on the prevalence and demographics 
of NPS use in the general population, it is only possible 
to apply conclusions drawn in this study to psychiatric 
inpatients. Due to the nature of the study design, it is also 
possible that NPS use prevalence was underestimated. 
Furthermore, reviewing discharge letters is vulnerable 
to two forms of bias: reporting bias, in which the quality 
of discharge letters is heterogeneous, and observer bias, 
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which arises due to variation in summarising recorded 
clinical impressions. The study aimed to reduce observer 
bias by reporting only explicitly positive NPS use cases and 
coding all others as non-NPS cases. This relies on clinicians 
directly inquiring into NPS use. Some discharge letters 
stated that NPS use was unknown but clinically suspected, 
which is perhaps a consequence of clinicians not routinely 
asking about NPS use when interviewing patients. In cases 
where NPS users were identified by clinical inquiry, inad-
equate recording of NPS types across both cohorts high-
lights poor recognition of the contribution NPS may have 
to psychiatric illness, perhaps due to a lack of relevant 
training for healthcare practitioners.42 The NEPTUNE 
project, a clinical guidance project, has made significant 
progress in resolving this gap by constructing an exten-
sive document detailing the presentation and manage-
ment of numerous NPS.43 Assuming inquiry by clinicians, 
the recording of NPS use is still limited as this approach 
relies on self-reporting by patients. It is also possible that 
patients using other substances are unintentionally also 
ingesting NPS as has been reported in a population aged 
18–25 years of club-goers who tested positive for a range 
of empathogen NPS despite denying any NPS use.44 
Ideally, laboratory analysis would have provided empirical 
evidence of NPS use and allowed for determination of the 
active ingredients ingested. Clinical screening for NPS 
is not routinely employed in clinical practice and limita-
tions in immunoassays, particularly the variable cross-reac-
tivity for different NPS lowers their sensitivity.45 However, 
chromatographic methods offer an alternative approach; 
liquid chromatography–tandem mass spectrometry of the 
urine has shown promise in identifying a diverse range of 
NPS and has been successfully implemented in a clinical 
setting.46 Use of such biochemical techniques would allow 
for reliable measurements in future studies relating to NPS 
use. While there are limitations associated with a retro-
spective review, it is useful for providing epidemiological 
findings and, as such, was deemed appropriate here for 
relatively simple data collection from an electronic patient 
database. Furthermore, this design provides a quantitative 
report on NPS users in contrast to the relative abundance 
of case reports in the literature, which do not allow for 
reliable systematic reviews to be conducted.47 In order 
to address the methodological issue of poor recording 
of NPS use by clinicians, a long-term prospective cohort 
study could be carried out using standardised pro formas 
with well-defined reporting criteria available on wards. 
This type of study would be of particular benefit across the 
UK in the period following the Psychoactive Substances 
Act (2016).22 More detailed analysis of NPS users will also 
identify whether these patients are previously known to 
suffer a psychiatric illness, what services they subsequently 
use and if these patients successively develop chronic 
psychiatric illnesses.
Generalisability
Since the TCDO placed on ethylphenidate and forfei-
ture orders of NPS within Edinburgh, there has been 
a reduction in the prevalence of NPS use in psychiatric 
admissions locally. This study does not aim to suggest 
there is a causal link between NPS and psychiatric illness, 
but other studies have provided evidence to support 
this link.15 The current findings instead suggest that 
prohibitive legislation coupled with the intensive and 
organised seizure of NPS may have contributed to the 
reduction of NPS-related admissions to acute psychi-
atric wards and to a local crisis team. The advent of 
the Psychoactive Substances Act (2016)22 criminalises 
the supply of NPS, and thus provides an opportunity to 
assess similar policy changes implemented on a national 
level. In response to the rise of NPS, New Zealand has 
adopted a regulatory licensing system whereby NPS can 
be approved for use if it is felt that there is a low risk of 
associated harm.48 Elsewhere, however, countries have 
taken ‘blanket ban’ stances similar to the Psychoactive 
Substances Act (2016),22 and these have failed to demon-
strate reductions in NPS use and availability.49 The 
present findings suggest that selective prohibition and 
general confiscation may be effective in reducing NPS-re-
lated admissions. While these findings are from a popu-
lation requiring psychiatric admission 6 months after 
public health measures were implemented, such results 
may be sustained and common to other clinical special-
ties. Future studies could be carried out to examine the 
impact of the Psychoactive Substances Act (2016)22 on 
psychiatric and general hospital admissions.
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